Month: April 2021

bardoxolone Treatment for Alport Syndrome Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome PLANO, Texas, April 26, 2021 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S.
0 Comments
NIH National Institute of Allergy and Infectious Diseases Director Anthony Fauci addresses the daily press briefing at the White House in Washington, January 21, 2021. Jonathan Ernst | Reuters White House chief medical advisor Dr. Anthony Fauci on Friday urged Americans to make sure they receive their second dose of the Covid-19 vaccines, saying the
0 Comments
NIH National Institute of Allergy and Infectious Diseases Director Anthony Fauci addresses the daily press briefing at the White House in Washington, January 21, 2021. Jonathan Ernst | Reuters White House chief medical advisor Dr. Anthony Fauci on Friday urged Americans to make sure they receive their second dose of the Covid-19 vaccines, saying the
0 Comments
Using ultra-high field magnetic resonance imaging (MRI) to map the brains of people with Down syndrome (DS), researchers from Case Western Reserve University, Cleveland Clinic, University Hospitals and other institutions detected subtle differences in the structure and function of the hippocampus–a region of the brain tied to memory and learning. Such detailed mapping, made possible
0 Comments
A pair of PD-1 immunotherapies used in advanced hepatocellular carcinoma (HCC) met sharply different receptions from FDA advisers reviewing accelerated approvals that failed to show benefit in confirmatory trials. In considering the two agents for previously treated HCC, the Oncologic Drugs Advisory Committee (ODAC) on Thursday unanimously recommended that FDA maintain its accelerated approval of
0 Comments